Clinical trials: Stage II Skin Cancer
Invasive Breast Cancer
Therapy for Locally Advanced Breast Cancer Using Doxil, Paclitaxel, and Cyclophosphamide With Avastin
This study will evaluate the rate of pathological complete response (pCR) to the sequential therapy of Doxil, paclitaxel, and cyclophosphamide with concurrent Avastin for patients with locally advanced invasive (T2,T3, Nany, M0)…
- Trial name
- NCT00635050
- Testing
- Doxil, Paclitaxel, Cyclophosphamide, Avastin
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Alabama at Birmingham
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Breast Cancer
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer after failing other treatments.
- Trial name
- ICE (NCT01097642)
- Testing
- Cetuximab, Ixabepilone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Metastatic Breast Cancer
A Study of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
This was a multi-institutional, open-label, single-arm, Phase II study of trastuzumab emtansine (T-DM1) administered by intravenous (IV) infusion to patients with human epidermal growth factor receptor 2 (HER2)-positive…
- Trial name
- NCT00509769
- Testing
- Trastuzumab emtansine [Kadcyla]
- Where
- 40 sites in United States
- Volunteers
- 112 people
- Sponsor
- Genentech, Inc.
Recurrent Skin Carcinoma, Skin Squamous Cell Carcinoma
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body.
- Trial name
- NCT02964559
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Emory University
Metastatic Breast Cancer
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
The goal of this trial is to determine the activity of erlotinib in a rationally selected population of women with ER-negative, PR-negative, HER2/neu-negative, EGFR-positive breast cancer.
- Trial name
- NCT00597597
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Rush University Medical Center
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer
A Clinical Trial of PM01183 in Metastatic Breast Cancer to assess the antitumor activity of PM01183 ,to evaluate whether the presence of a known germline mutation in BRCA 1/2 predicts response to PM01183 in Metastatic Breast…
- Trial name
- NCT01525589
- Testing
- PM01183
- Where
- 9 sites in United States, Spain
- Volunteers
- 111 people
- Sponsor
- PharmaMar
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
This phase II trial studies how well hypofractionated radiation therapy works in treating patients with stage 0-IIB breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage 0 Breast Cancer, Stage I Breast Cancer
- Trial name
- NOVEMBER (NCT03345420)
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Utah
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295893
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- City of Hope Medical Center
HER2-positive Breast Cancer, Breast Adenocarcinoma
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib.
- Conditions
- HER2-positive Breast Cancer, Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7
- Trial name
- NCT03094052
- Testing
- Neratinib, Trastuzumab, Loperamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer
This phase II trial studies how well giving pazopanib hydrochloride and anastrozole before surgery works in treating patients with stage II-III estrogen receptor-positive breast cancer.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Male Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT01394211
- Testing
- anastrozole, pazopanib hydrochloride, therapeutic conventional surgery
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Metastatic Breast Cancer
PhII ICb With/Without Erbitux in MBC Pts
The purpose of this study is to determine the objective response rates produced by irinotecan and carboplatin therapy with or without Erbitux in patients with Metastatic Breast Cancer.
- Trial name
- CA225200 (NCT00248287)
- Testing
- Irinotecan + Carboplatin, irinotecan + Carboplatin + erbitux
- Where
- 59 sites in United States
- Volunteers
- 154 people
- Sponsor
- US Oncology Research
Breast Cancer
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Breast cancer is the most common malignancy in the U.S. Targeted therapies such as tamoxifen have been revolutionary in reducing tumor recurrences and mortality in early breast cancer.
- Trial name
- HELEX (NCT00999804)
- Testing
- Lapatinib, Letrozole, Trastuzumab
- Where
- 8 sites in United States
- Volunteers
- 128 people
- Sponsor
- Baylor Breast Care Center
Breast Cancer
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
- Trial name
- NCT04542135
- Testing
- Sulindac Pill
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Alison Stopeck
Metastatic Melanoma
Metronomic Therapy in Patients With Metastatic Melanoma
SUMMARY: Metronomic Therapy in Patients with Metastatic Melanoma: A Phase II Study of Low Dose Vinblastine, Cyclophosphamide, and Dacarbazine. Patients with measurable metastatic melanoma are eligible.
- Trial name
- NCT01542255
- Testing
- vinblastine, Cyclophosphamide, dacarbazine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer
RATIONALE: Pyridoxine (vitamin B6) and topical urea/lactic acid-based cream may prevent or lessen hand-foot syndrome caused by chemotherapy.
- Conditions
- Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00296036
- Testing
- pyridoxine hydrochloride, urea/lactic acid-based topical cream
- Where
- 231 sites in United States
- Volunteers
- 137 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.